Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jorge E. Cortes, Bogdan Muresan, Carla Mamolo, Joseph C. Cappelleri, Rocco J. Crescenzo, Yun Su, Carlo Gambacorti-Passerini, Bart Heeg & B. Douglas Smith. (2019) Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion 35:9, pages 1615-1622.
Read now
Read now
Guray Saydam, Ibrahim Celalettin Haznedaroglu, Leylagul Kaynar, Akif S. Yavuz, Ridvan Ali, Birol Guvenc, Olga M. Akay, Zafer Baslar, Ugur Ozbek, Mehmet Sonmez, Demet Aydin, Mustafa Pehlivan, Bulent Undar, Simten Dagdas, Orhan Ayyildiz, Diyar Z. Akkaynak, Ilkiz M. Dag & Osman Ilhan. (2016) Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy 17:14, pages 1851-1858.
Read now
Read now
Taichi Hirano, Miyuki Hashimoto, Yu Korogi, Takahiro Tsuji, Kei Miyanaka, Hiroshi Yamasaki & Hiroyuki Tsuda. (2016) Dasatinib-induced nephrotic syndrome. Leukemia & Lymphoma 57:3, pages 726-727.
Read now
Read now
Lisa J. McGarry, Yaozhu J. Chen, Victoria Divino, Shibani Pokras, Catherine R. Taylor, Julie Munakata, Christopher C. Nieset, Hui Huang, Elias Jabbour & Daniel C. Malone. (2016) Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Current Medical Research and Opinion 32:2, pages 289-299.
Read now
Read now
Eylem Eliacik, Ayse Isik, Cisel Aydin, Aysegul Uner, Salih Aksu, Nilgun Sayinalp, Haluk Demiroglu, Hakan Goker, Yahya Buyukasik, Osman Ozcebe & Ibrahim C. Haznedaroglu. (2015) Bone marrow fibrosis may be an effective independent predictor of the ‘TKI drug response level’ in chronic myeloid leukemia. Hematology 20:7, pages 392-396.
Read now
Read now
Omar Al Ustwani, Elizabeth A Griffiths, Eunice S Wang & Meir Wetzler. (2014) Omacetaxine mepesuccinate in chronic myeloid leukemia. Expert Opinion on Pharmacotherapy 15:16, pages 2397-2405.
Read now
Read now
Articles from other publishers (16)
Mufide Okay & Ibrahim C. Haznedaroglu. 2021. Protein Kinase-mediated Decisions Between Life and Death. Protein Kinase-mediated Decisions Between Life and Death
383
393
.
Jee Hyun Kong, Elliott F. Winton, Leonard T. Heffner, Manila Gaddh, Brittany Hill, Jessica Neely, Angela Hatcher, Meena Joseph, Martha Arellano, Fuad El-Rassi, Audrey Kim, Jean Hanna Khoury & Vamsi K. Kota. (2020) Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. Journal of Clinical Medicine 9:5, pages 1542.
Crossref
Crossref
Rafiye Ciftciler, Emine Arzu Saglam, Ayten Inanc, Osman Ozcebe & Ibrahim Celalettin Haznedaroglu. (2019) A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia. Cancer Genetics 237, pages 78-81.
Crossref
Crossref
Umit Y. Malkan & Ibrahim C. Haznedaroglu. (2018) Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia. Open Medicine 14:1, pages 22-24.
Crossref
Crossref
Bader Alharbi, Samer Alamri, Ahmed Mahdi & Siham Marghalani. (2018) Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature. Case Reports in Dermatological Medicine 2018, pages 1-4.
Crossref
Crossref
Bingyu Yang, Chang Wang, Yiyu Xie, Liangjing Xu, Xiaojin Wu & Depei Wu. (2018) Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients. Cancer Science 109:3, pages 777-784.
Crossref
Crossref
Rahem Mahdy Rahem, Adel Abdulhussien Abuhmood & Luwaa Hussein. (2017) Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq. Karbala International Journal of Modern Science 3:4, pages 231-240.
Crossref
Crossref
Marcel Massoud, Riwa Sakr, Fouad Kerbage, Joseph Makdissi, Jenny Hawi, Layale Rached, Fady Nasr & Georges Chahine. (2017) Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon. Clinical Lymphoma Myeloma and Leukemia 17, pages S111-S115.
Crossref
Crossref
Isabel Ben-Batalla, Robert Erdmann, Heather Jørgensen, Rebecca Mitchell, Thomas Ernst, Gunhild von Amsberg, Philippe Schafhausen, Janna L. Velthaus, Stephen Rankin, Richard E. Clark, Steffen Koschmieder, Alexander Schultze, Subir Mitra, Peter Vandenberghe, Tim H. Brümmendorf, Peter Carmeliet, Andreas Hochhaus, Klaus Pantel, Carsten Bokemeyer, G. Vignir Helgason, Tessa L. Holyoake & Sonja Loges. (2017) Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical Cancer Research 23:9, pages 2289-2300.
Crossref
Crossref
Marcel Massoud, Fadi Nasr, Riwa Sakr, Jenny Hawi, Fouad Kerbage & Georges Chahine. (2016) Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon. Clinical Lymphoma Myeloma and Leukemia 16, pages S101-S104.
Crossref
Crossref
Mario Ojeda-Uribe, Sylvain Merieau, Marie Guillon, Olivier Aujoulat, Olivier Hinschberger, Jean-Claude Eisenmann, David Kenizou, Agathe Debliquis, Agnès Veyradier & François Chantrel. (2015) Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate. Journal of Oncology Pharmacy Practice 22:2, pages 361-370.
Crossref
Crossref
Umit Y. Malkan, Gursel Gunes, Sezgin Etgul, Tuncay Aslan, Seda Aydin & Ibrahim C. Haznedaroglu. (2016) Reply. Annals of Pharmacotherapy 50:4, pages 336-336.
Crossref
Crossref
Umit Yavuz Malkan, Gursel Gunes, Sezgin Etgul, Tuncay Aslan, Seda Balaban & Ibrahim C. Haznedaroglu. (2015) Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib. Annals of Pharmacotherapy 49:6, pages 740-742.
Crossref
Crossref
Gillian A Horne, Ross Kinstrie & Mhairi Copland. (2015) Novel drug therapies in myeloid leukemia: a patent review. Pharmaceutical Patent Analyst 4:3, pages 187-205.
Crossref
Crossref
Nader I. Ai-DewikAndrew P. JewellMohammed A. YassinHisham M. Morsi. (2015) Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar. Biomarkers in Cancer 7, pages BIC.S31427.
Crossref
Crossref
Yahiya Y. Syed, Paul L. McCormack & Greg L. Plosker. (2014) Bosutinib: A Review of Its Use in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. BioDrugs 28:1, pages 107-120.
Crossref
Crossref